PRODUCT PORTFOLIO INOVIQ’s product portfolio includes commercial exosome isolation products and an adjunct bladder cancer test, clinicalstage diagnostics for ovarian cancer screening and breast cancer monitoring, and a preclinical-stage CAR-exosome therapeutic program for solid tumours. Our pipeline priorities are our EXO-OC screening test for ovarian cancer and CAR-exosome therapy for triple negative breast cancer. Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 7 Annual Report 2025 Research Tools Indication Use Discovery Verification Validation In-market Next Milestone EXO-NET Multiple Pan-EV Capture Sales Growth & Collaborations NEURO-NET Neurology Brain Derived-EV Capture Collaborations TEXO-NET Oncology Tumour Derived-EV Capture Validation data | 2H25 Diagnostics Indication Use Discovery Assay Development Clinical In-market Next Milestone EXO-OC Ovarian Cancer Screening Commence clinical validation | 2H25 neuCA15-3 Breast Cancer Monitoring Partnering | 2H25 hTERT ICC Bladder Cancer Adjunct to Cytology Therapeutics Indication Use Discovery Pre-clinical Clinical In-market Next Milestone EEV-001 Breast Cancer CAR-Exosome therapy In vivo data | 2H25 RUO RUO RUO LDT IVD-CLASS 1 US IVD
RkJQdWJsaXNoZXIy MjE2NDg3